Masimo Co. (NASDAQ:MASI) COO Bilal Muhsin sold 10,000 shares of Masimo stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the completion of the sale, the chief operating officer now directly owns 10,000 shares in the company, valued at approximately $1,400,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Bilal Muhsin also recently made the following trade(s):
- On Wednesday, June 5th, Bilal Muhsin sold 10,000 shares of Masimo stock. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00.
Shares of MASI stock opened at $144.32 on Thursday. Masimo Co. has a 1 year low of $96.14 and a 1 year high of $147.91. The firm has a market cap of $7.64 billion, a price-to-earnings ratio of 47.63, a price-to-earnings-growth ratio of 2.75 and a beta of 1.09.
A number of hedge funds have recently modified their holdings of MASI. FMR LLC raised its holdings in Masimo by 17.8% during the 4th quarter. FMR LLC now owns 3,889,562 shares of the medical equipment provider’s stock valued at $417,622,000 after acquiring an additional 587,587 shares during the period. Norges Bank bought a new stake in Masimo during the 4th quarter valued at $53,357,000. Fundsmith LLP bought a new stake in Masimo during the 4th quarter valued at $51,470,000. Wellington Management Group LLP raised its holdings in Masimo by 941.9% during the 1st quarter. Wellington Management Group LLP now owns 477,320 shares of the medical equipment provider’s stock valued at $66,003,000 after acquiring an additional 431,508 shares during the period. Finally, Lord Abbett & CO. LLC bought a new stake in Masimo during the 4th quarter valued at $31,807,000. 83.66% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts recently commented on the stock. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. Zacks Investment Research cut shares of Masimo from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. Piper Jaffray Companies lifted their price target on shares of Masimo from $140.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating on shares of Masimo in a report on Tuesday, April 9th. Finally, UBS Group lifted their price target on shares of Masimo from $147.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $154.25.
ILLEGAL ACTIVITY WARNING: This piece was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2019/06/13/masimo-co-nasdaqmasi-coo-bilal-muhsin-sells-10000-shares.html.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.